Amgen's Repatha Emerges Unscathed In GLAGOV PCSK9 Imaging Study

Full data from GLAGOV imaging study shows value of driving LDL below 60 mg/dL and presents no red flags for outcomes data due in first quarter of 2017.

More from Clinical Trials

More from R&D